Drug intelligence / Profile preview

besifloxacin + ciprofloxacin + gatifloxacin + levofloxacin + moxifloxacin + ofloxacin

Development stage
Unknown
Lead developer
Valeant Pharmaceuticals
Modality
Small Molecules
Administration
Ophthalmic, Oral, Intravenous, Otic
01

Overview

This is a combination of six fluoroquinolone antibiotics—besifloxacin, ciprofloxacin, gatifloxacin, levofloxacin, moxifloxacin, and ofloxacin. All are synthetic broad-spectrum antibacterial agents that act by inhibiting bacterial DNA gyrase and topoisomerase IV. This inhibition disrupts DNA replication and transcription in susceptible bacteria, leading to cell death. These drugs are primarily used to treat a variety of bacterial infections including respiratory tract infections (such as pneumonia), urinary tract infections, skin infections, and ocular infections. Each agent has unique pharmacokinetic properties and antimicrobial spectra but shares the same core mechanism of action as bactericidal inhibitors of bacterial topoisomerases[3][6][8]. The use of multiple fluoroquinolones together is not standard clinical practice due to overlapping mechanisms and potential for increased toxicity or resistance.

02

Targets

DNA gyraseTopo IV (Bacterial Topoisomerase IV)

Beyond the preview

Go deeper on besifloxacin + ciprofloxacin + gatifloxacin + levofloxacin + moxifloxacin + ofloxacin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on besifloxacin + ciprofloxacin + gatifloxacin + levofloxacin + moxifloxacin + ofloxacin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call